HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

Cited by (477)

Items 301–400 of 477

1. Successful Strategies in the Discovery of Small-Molecule Epigenetic Modulators with Anticancer Potential
   Juan Bayo, Maithili P. Dalvi, Elisabeth D. Martínez · 2015 · Future Medicinal Chemistry
2. ETV6-RUNX1 interacts with a region in SPIB intron 1 to regulate gene expression in pre-B-cell acute lymphoblastic leukemia
   Li Xu, Alyssa Francis, Shereen A. Turkistany, Devanshi Shukla, Alison Wong, Carolina R. Batista, Rodney P. DeKoter · 2019 · Experimental Hematology
3. HDACs and their inhibitors in immunology: teaching anticancer drugs new tricks
   David P. Fairlie, Matthew J. Sweet · 2012 · Immunology and Cell Biology
4. Approaches for discovering novel bioactive small molecules targeting autophagy
   Hui‐Yun Hwang, Sung Min Cho, Ho Jeong Kwon · 2017 · Expert Opinion on Drug Discovery
5. The Implication of Cancer Progenitor Cells and the Role of Epigenetics in the Development of Novel Therapeutic Strategies for Chronic Myeloid Leukemia
   Stephanie M. Tortorella, Andrew Hung, Tom C. Karagiannis · 2014 · Antioxidants and Redox Signaling
6. Epigenetic Regulators: New Therapeutic Targets for Soft Tissue Sarcoma
   Pingyu Zhang, Raphael E. Pollock · 2014 · Cancer Cell & Microenvironment
7. A quinazoline-based HDAC inhibitor affects gene expression pathways involved in cholesterol biosynthesis and mevalonate in prostate cancer cells
   Zhiyin Lin, Karen Suzanne Bishop, Hamish S. Sutherland, Gareth Marlow, P Murray, William Alexander Denny, Lynnette Robyn Ferguson · 2016 · Molecular BioSystems
8. Strong Correlation between the Expression Levels of HDAC4 and SIRT6 in Hematological Malignancies of the Adults
   Zsuzsanna Gaál, Éva Oláh, László Rejtő, Ferenc Erdődi, László József Csernoch · 2016 · Pathology & Oncology Research
9. OBP‑801, a novel histone deacetylase inhibitor, induces M‑phase arrest and apoptosis in rhabdomyosarcoma cells
   Chihiro Tomoyasu, Ken Kikuchi, Daisuke Kaneda, Shigeki Yagyu, Mitsuru Miyachi, Kunihiko Tsuchiya, Tomoko Iehara, Toshiyuki Sakai, Hajime Hosoi · 2018 · Oncology Reports
10. Design, synthesis and biological evaluation of 4-piperidin-4-yl-triazole derivatives as novel histone deacetylase inhibitors
    Miao He, Jianjun Gao, Zishuo Mou, Baolei Wang, Li Zhang, Li Su, Yantao Han, Yepeng Luan · 2019 · BioScience Trends
11. Histone Deacetylase (HDAC) Inhibitors in Recent Clinical Trials for Cancer Therapy
    Kristina Keller, Manfred Jung · 2013 · Springer eBooks
12. Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppresses cell proliferation and induces apoptosis in breast cancer cells
    Xinmiao Yang, Ning Zhang, Zeliang Shi, ZHANGYU YANG, Xichun Hu · 2014 · Molecular Medicine Reports
13. Focused conformational sampling in proteins
    Marco Bacci, Cassiano Langini, Jiří Vymětal, Amedeo Caflisch, Andreas Vitalis · 2017 · The Journal of Chemical Physics
14. Histone Signatures Predict Therapeutic Efficacy in Breast Cancer
    Shamim Ara Mollah, Shankar Subramaniam · 2020 · IEEE Open Journal of Engineering in Medicine and Biology
15. Novel Conjugated Quinazolinone-Based Hydroxamic Acids: Design, Synthesis and Biological Evaluation
    Tran Khac Vu, Nguyễn Thị Thanh, Nguyễn Văn Minh, Nguyen Huong Linh, Nguyễn Thị Phương Thảo, Trương Thuc Bao Nguyen, Doan Thi Hien, Luu Van Chinh, Ta Hong Duc, Lai Duc Anh et al. · 2020 · Medicinal Chemistry
16. Tailored Quinolines Demonstrate Flexibility to Exert Antitumor Effects through Varied Mechanisms-A Medicinal Perspective
    Sachin Sharma, Arshdeep Singh, Sahil Sharma, Ram Sharma, Jagjeet Singh, Nihar Kinarivala, Kunal Nepali, Jing‐Ping Liou · 2020 · Anti-Cancer Agents in Medicinal Chemistry
17. The Role of Chromatin-Associated Proteins in Cancer
    Kristian Helin, Saverio Minucci · 2016 · Annual Review of Cancer Biology
18. HDAC Inhibitors: Novel Immunosuppressants for Allo‐ and Xeno‐ Transplantation
    Qing Zhang, Yifan Dai, Zhiming Cai, Lisha Mou · 2018 · ChemistrySelect
19. Effect of sodium butyrate on HDAC8 mRNA expression in colorectal cancer cell lines and molecular docking study of LHX1 - sodium butyrate interaction
    Flora Forouzesh, Mahsa Ghiaghi, Hamzeh Rahimi · 2020 · EXCLI journal
20. Prognostic model construction and validation of esophageal cancer cellular senescence-related genes and correlation with immune infiltration
    Shiyao Zheng, Nan Lin, Qing Wu, Hongxin He, Chunkang Yang · 2023 · Frontiers in Surgery
21. Susceptibility of hepatoma-derived cells to histone deacetylase inhibitors is associated with ID2 expression
    Ryouichi Tsunedomi, Norio Iizuka, Sawako Harada, Masaaki Oka · 2013 · International Journal of Oncology
22. Depsipeptide and roxithromycin induce apoptosis of lymphoma cells by blocking extracellular signal‐regulated kinase activation
    Sohshi Morimura, Makoto Sugaya, Hiromichi Kai, Tomomitsu Miyagaki, Yoshihide Asano, Yayoi Tada, Takafumi Kadono, Takashi Murakami, Sinichi Sato · 2014 · The Journal of Dermatology
23. Uhrf1 regulates H3K9me2 modification of mTOR to inhibit the effect of autophagy in myocardial ischemia-reperfusion injury
    Han-Geng Li, Wen-Hua Tian, Cun-Lan Qin, Rong-Rong Ye, Donghua Liu, Huiwen Liu · 2021 · Aging
24. Biomarkers of Histone Deacetylase Inhibitor Activity in a Phase 1 Combined-Modality Study with Radiotherapy
    Anne Hansen Ree, Marie Grøn Sælen, Erta Kalanxhi, Ingrid H. G. Østensen, Kristina Schee, Kathrine Røe Redalen, Torveig Weum Abrahamsen, Svein Dueland, Kjersti Flatmark · 2014 · PLoS ONE
25. Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK
    Carole Brosseau, Christelle Dousset, Cyrille Touzeau, Sophie Maïga, Philippe Moreau, Martine Amiot, Steven Le Gouill, Catherine Pellat‐Deceunynck · 2014 · Cell Death and Disease
26. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma
    Borui Zhao, Zhi Huang, Zhongxiang Qin, Yongtao Li, Tianqi Wang, Linchuan Wang, Wei Zhou, Chenhua Yu, Xin Wang, Shengyong Yang et al. · 2019 · Cellular Physiology and Biochemistry
27. Design, synthesis, and antitumor activity evaluation of carbazole derivatives with potent HDAC inhibitory activity
    Likun Sun, Leiqiang Han, Liang N. Zhang, Chen Chen, Chengyun Zheng · 2023 · Medicinal Chemistry Research
28. SIRT2 Inhibition by AGK2 Promotes Perinuclear Cytoskeletal Organisation and Reduces Invasiveness of MDA-MB-231 Triple-Negative Breast Cancer Cells in Confined In Vitro Models
    Emily Jessop, Natalie Young, Beatriz Garcia-Del-Valle, Jack T. Crusher, Bogusław Obara, Iakowos Karakesisoglou · 2024 · Cells
29. Combined Treatment of ATRA with Epigenetic Drugs Increases Aggressiveness of Glioma Xenografts.
    Thomas Schmoch, Zoltan Gal, Andreas Möck, Jan Mossemann, Bernd Lahrmann, Niels Grabe, Peter Schmezer, Felix Lasitschka, Philipp Beckhove, Andreas Wilhelm Unterberg et al. · 2016 · PubMed
30. Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo
    Wei Ye, Fangzheng Zhou, Zhenyu Lin, Liangliang Shi, Ai Huang, Tao Liu, Dandan Yu, Gang Wu · 2018 · Anti-Cancer Drugs
31. Calcitriol downregulates fibroblast growth factor receptor 1 through histone deacetylase activation in HL-1 atrial myocytes
    Ting‐Wei Lee, Ting-I Lee, Yung‐Kuo Lin, Yu‐Hsun Kao, Yi‐Jen Chen · 2018 · Journal of Biomedical Science
32. Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma.
    Masumeh Sanaei, Fraidoon Kavoosi · 2021 · PubMed Central
33. Sodium Valproate Is Effective Against Botrytis cinerea Infection of Tomato by Enhancing Histone H3 Acetylation-Directed Gene Transcription and Triggering Tomato Fruit Immune Response
    Yang Xu, Yameng Wang, Lulu Wang, Wenxing Liang, Qianqian Yang · 2022 · Phytopathology
34. 4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide – A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation
    Katharina Mahal, Philip Kahlen, Bernhard Biersack, Rainer Schobert · 2015 · Experimental Cell Research
35. A248, a novel synthetic HDAC inhibitor, induces apoptosis through the inhibition of specificity protein 1 and its downstream proteins in human prostate cancer cells
    Eun-Sun Choi, Gyoonhee Han, Song‐Kyu Park, Kiho Lee, Hyun-Jung Kim, Sung Dae Cho, Hwan Mook Kim · 2013 · Molecular Medicine Reports
36. A new ureido-substituted amino acid from the tubers of Gymnadenia conopsea
    Pengcheng Lin, Jing Yao, Jiang Wu, Jin Tian, Yi Bao, Sheng Hao Lin · 2016 · Chinese Chemical Letters
37. Natural Agents-Mediated Targeting of Histone Deacetylases
    Ammad Ahmad Farooqı, Syed Kamran‐ul‐Hassan Naqvi, Aliye Aras, Onur Yanar, Sobia Tabassum, Muhammad Sheeraz Ahmad, Qaisar Mansoor, Mohamed Saad El Ashry, Muhammad Ismail, George E. Naoum et al. · 2017 · Archivum Immunologiae et Therapiae Experimentalis
38. Panobinostat for the treatment of multiple myeloma
    Minal J. Surati, Kelly Valla, Katherine Sanvidge Shah, Elyse Hall Panjic, Sagar Lonial · 2015 · Expert Opinion on Orphan Drugs
39. SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model
    Xuguang Zhu, Dong Wook Kim, Li Zhao, Mark C. Willingham, Sheue-yann Cheng · 2016 · Endocrine Related Cancer
40. YF343, A Novel Histone Deacetylase Inhibitor, Combined with CQ to Inhibit- Autophagy, Contributes to Increased Apoptosis in Triple- Negative Breast Cancer
    Na Liu, Tingting Luo, Jing Zhang, Li-na Han, Wenqi Duan, Wenxia Lu, Huiran Qiu, Yan Lin, Yongmei Wu, Hua Zhang et al. · 2023 · Current Medicinal Chemistry
41. A Review on Important Histone Acetyltransferase (HAT) Enzymes as Targets for Cancer Therapy
    Mohammad Ghanbari, Reza Safaralizadeh, Kiyanoush Mohammadi · 2018 · Current Cancer Therapy Reviews
42. OleD Loki as a Catalyst for Hydroxamate Glycosylation
    Ryan R. Hughes, Khaled A. Shaaban, Larissa V. Ponomareva, Jamie Horn, Chunhui Zhang, Chang‐Guo Zhan, S. Randal Voss, Markos L. Leggas, Jon S. Thorson · 2019 · ChemBioChem
43. Single-suture craniosynostosis and the epigenome: current evidence and a review of epigenetic principles
    Othman Bin-Alamer, Adrian E. Jimenez, Tej Deepak Azad · 2021 · Neurosurgical FOCUS
44. Liver Cancer (Hepatocellular Carcinoma)
    Shane O’Grady, Matthew W. Lawless · 2015 · Elsevier eBooks
45. Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program
    Pier Luigi Zinzani, Cinzia Pellegrini, Giuseppe Cerciello, Federico Monaco, Stefano Volpetti, Annalisa Peli, Emanuele Angelucci, Paolo Corradini, Maria Christina Cox, Attilio Guarini et al. · 2016 · Leukemia & lymphoma/Leukemia and lymphoma
46. Advances in Drug Discovery and Development in Geriatric Psychiatry
    Alexander C. Conley, PAUL A. NEWHOUSE · 2018 · Current Psychiatry Reports
47. An ELISA method to assess HDAC inhibitor-induced alterations to P. falciparum histone lysine acetylation
    Eva Hesping, Tina S. Skinner‐Adams, Gillian M. Fisher, Thomas Kurz, Katherine T. Andrews · 2020 · International Journal for Parasitology Drugs and Drug Resistance
48. Preparation and characterization of vorinostat-coated beads for profiling of novel target proteins
    Congcong Lu, Kai Zhang, Yi Zhang, Minjia Tan, Yijun Li, Xiwen He, Yukui Zhang · 2014 · Journal of Chromatography A
49. Effects of cisplatin and panobinostat on human mesothelial (Met-5A) and malignant pleural mesothelioma (MSTO-211H) cells
    K.E. Gultekin, M.K. Yurdakonar, Emel Yaman, U.S. Yuce, Akın Yılmaz, Ebru Alp, Ali Çelik, Şevki Mustafa Demiröz, Hacer İlke Önen · 2013 · Genetics and Molecular Research
50. Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy
    Erta Kalanxhi, Karianne Risberg, Imon Barua, Svein Dueland, Stein Waagene, Solveig Norheim Andersen, Solveig Pettersen, Jessica Margareta Lindvall, Kathrine Røe Redalen, Kjersti Flatmark et al. · 2016 · Cancer Research and Treatment
51. Identification of new scaffolds with anti-tumor action toward human glioblastoma cells
    Aleksandra Ellert‐Miklaszewska, Sabrina Dallavalle, Loana Musso, Nadine Martinet, Kamil Wojnicki, Bozena Kaminska · 2016 · MedChemComm
52. Epigenetic Biomarkers of Disease
    Philip D. Voyias, Abhilasha J. Patel, Ramesh Pulendran Arasaradnam · 2016 · Elsevier eBooks
53. Solid-Phase Parallel Synthesis of Dual Histone Deacetylase-Cyclooxygenase Inhibitors
    Luisa M. Bachmann, Maria Hanl, Felix Feller, Laura Sinatra, Andrea Schöler, Jens Pietzsch, Markus Laube, Finn K. Hansen · 2023 · Molecules
54. Unraveling the mechanism of microRNA-134 in colon cancer progression: Targeting KRAS and PIK3CA for cell cycle control and histone deacetylase regulation
    Ganesan Jothimani, Diptimayee Das, Surajit Pathak, Sarubala Malayaperumal, Hong Zhang, Xiao-Feng Sun, Antara Banerjee · 2024 · Experimental Cell Research
55. Pharmacoepigenetics of Histone Deacetylase Inhibitors in Cancer
    Nikolaos Garmpis, Christos Damaskos, Anna Garmpi, Serena I. Valsami, Dimitrios Dimitroulis · 2019 · Elsevier eBooks
56. Ibrutinib combined with low‐dose histone deacetylases inhibitor chidamide synergistically enhances the anti‐tumor effect in B‐cell lymphoma
    Hui Yu, Lan Mi, Weimin Zhang, Yingying Ye, Miaomiao Li, Dingyao Hu, Jiaowu Cao, Dedao Wang, Xiaogan Wang, Ning Ding et al. · 2022 · Hematological Oncology
57. Role of epigenetically regulated inflammation in renal diseases
    Juan Jin, Yaru Yang, Qian Gong, Jia-nan Wang, Wei‐Jian Ni, Jiagen Wen, Xiao‐Ming Meng · 2022 · Seminars in Cell and Developmental Biology
58. TMP269, a small molecule inhibitor of class IIa HDAC, suppresses RABV replication in vitro
    Juanbin Yin, Shasha Wang, Shanhui Ren, Zhengji Liang, Junwei Ge, Yuefeng Sun, Xiangping Yin, Xiangwei Wang · 2023 · Frontiers in Microbiology
59. Differential effect of heterocyclic d-ribofuranoside derivatives on human prostate cancer cell viability and cell cycle progression
    Geraldine Gueron, Romina E. Avanzo, Federico Schuster, María Noelia Carabelos, Elba Susana Vazquez, Mirta Liliana Fascio, Norma B. D’Accorso · 2014 · Biomedicine & Pharmacotherapy
60. The in vitro apoptotic effects of A248 and A1659, newly synthetic histone deacetylase inhibitors in oral cancer cells
    J‐A Shin, Gyoonhee Han, S‐K Park, K Lee, H Kim, S‐D Cho, HM Kim · 2013 · Oral Diseases
61. Vorinostat Downregulates CD30 and Decreases Brentuximab Vedotin Efficacy in Human Lymphocytes
    Zainul S. Hasanali, Elliot M. Epner, David J. Feith, Thomas P. Loughran, Clare E. Sample · 2014 · Molecular Cancer Therapeutics
62. HDAC inhibitor SB939 potentiates TRAIL-induced apoptosis in colorectal cancer cells
    Min Woo Shin, Seung Young Seo, Se‐Lim Kim, Sang-Wook Kim · 2023 · Cellular and Molecular Biology
63. Molecular pathways and potential therapeutic targets in glioblastoma multiforme
    Zabi Wardak, Kevin S. Choe · 2013 · Expert Review of Anticancer Therapy
64. Histone modifications and depression: epigenetic mechanisms, therapeutic targets, and translational outlook
    Lv, Liang-Zhen, Wang, Zhao-Di, Ren, Jia-jie, Li, Lu-Hao, Liu, Xian-bao, Li, Jia-li, Zhu, Hui, Jiang, Bei, Han, Ya-peng, Zhou, Xue-ming et al. · 2026 · Frontiers in Genetics
65. Semisynthesis of Glycosmis pentaphylla Alkaloid Derivatives: Pyranoacridone-Hydroxamic Acid Cytotoxic Conjugates with HDAC and Topoisomerase II α Dual Inhibitory Activity
    Parusu Kavya Teja, Bao Q. Ly, Vinal Upadhyay, Sourav Das, Santosh Kumar Behera, Amit Mandoli, Dhaval K. Shah, Siddheshwar Kisan Chauthe · 2025 · Journal of Natural Products
66. Tropolones and Thailandepsin B as Lead-like Natural Compounds in the Development of Potent and Selective Histone Deacetylase Inhibitors
    Dilipkumar Pal, Padum Lal · 2023 · Current Drug Targets
67. Histone Methyltransferase Activity Assays
    Haiching Ma, Konrad T. Howitz, Kurumi Y. Horiuchi, Yuren Wang · 2015 · Royal Society of Chemistry eBooks
68. Gene Transcription as a Therapeutic Target in Leukemia
    Alvina I. Khamidullina, Ekaterina A. Varlamova, Nour Alhuda Hammoud, Margarita A. Yastrebova, Alexandra V. Bruter · 2021 · International Journal of Molecular Sciences
69. Synthesis and Anticancer Potential of New Hydroxamic Acid Derivatives as Chemotherapeutic Agents
    Işıl Nihan Korkmaz, Hasan Özdemіr · 2022 · Applied Biochemistry and Biotechnology
70. Systematic Analysis of Time-Series Gene Expression Data on Tumor Cell-Selective Apoptotic Responses to HDAC Inhibitors
    Yunfeng Qi, Yanxin Huang, Yan Dong, Lihua Zheng, Yongli Bao, Luguo Sun, Yin Wu, Chunlei Yu, Hongyu Jiang, Yuxin Li · 2014 · Computational and Mathematical Methods in Medicine
71. Radiosensitizing Efficacy of Diosmin- Hesperidin Complex Against Ehrlich Solid Carcinoma in Mice, A Potential Role of Histone Deacetylase and Pro-angiogenic Chaperones Targeting
    Mohamed Khairy Abd, Asmaa Abu Bakr · 2017 · International Journal of Cancer Research
72. Diffuse Midline Glioma – Diffuse Intrinsic Pontine Glioma
    Mohammad Hassan A. Noureldine, Nir Shimony, George I. Jallo · 2020 · Springer eBooks
73. Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma: a phase 2 clinical trial
    Elsa Hallab, Jennifer N. Durham, Rosalind Walker, Leslie Cope, Soren Charmsaz, Nicole Groß, Dimitrios N. Sidiropoulos, Alexei Hernandez, James Leatherman, Sarah Mitchell et al. · 2025 · Epigenetics Communications
74. Safety and Efficacy of Givinostat for Patients with Muscular Dystrophy: A Systematic Review
    Prasanjit Das, Bisweswar Ojha, Alapan Das, Bhairav Kumar Pathak, Kaushik Mukhopadhyay · 2025 · Pharmacology
75. Novel selective indole based histone deacetylase 10 inhibitors as anticancer therapeutics
    Amer Hussein Tarawneh, Salah A. Al‐Trawneh, Talha Z. Yesiloglu, Matthes Zessin, Dina Robaa, Cyril Bařinka, Mike Schutkowski, Wolfgang Sippl, Samir Anis Ross · 2025 · Scientific Reports
76. Epigenetic mechanisms and therapeutic advances in breast cancer: From molecular insights to clinical applications
    Mir Shahid Maqbool, Joseph W. Landry, Swadesh Kumar Das, Paul B. Fisher · 2025 · Advances in cancer research
77. Impact of epigenetic modifiers on the immune system
    Sajad Ahmad Bhat, Shalini Kashipathi Sureshbabu, Chinna Susan Philip, Shubhada Vivek Chiplunkar · 2020 · Elsevier eBooks
78. High-Throughput Screening and Proteomic Characterization of Compounds Targeting Myeloid-Derived Suppressor Cells
    Johannes Krumm, Elissaveta P. Petrova, Severin Lechner, Julia Mergner, Hans-Henning Boehm, Alessandro Prestipino, Dominik Steinbrunn, Marshall L. Deline, Lisa Koetzner, Christina Schindler et al. · 2023 · Molecular & Cellular Proteomics
79. Smoking and bladder cancer: insights into pathogenesis and public health implications from a bibliometric analysis (1999–2023)
    Yang Wang, Hancheng Zhou, Zhicheng Tang, Zhaohui He, Hui Zhuo, Yi Huang, Jianqiu Kong · 2025 · Substance Abuse Treatment Prevention and Policy
80. Bromodomains as Anticancer Targets
    P. Filippakopoulos, Stefan Knapp · 2016 · Elsevier eBooks
81. Failure of Romidepsin to Treat Relapsed/Refractory Peripheral T-Cell Lymphoma in Children: A Single-center Experience
    Sneha Tandon, Jack Luke Bartram, Lianna G. Kyriakopoulou, Nisha Kanwar, Winnie W. Lo, Scott Davidson, Angela Punnett, Adam Shlien, Johann K. Hitzler, David M. Malkin et al. · 2020 · Journal of Pediatric Hematology/Oncology
82. Novel Therapeutic Targets for Human African Trypanosomiasis
    Shikha Girdhar, Amit Girdhar, Viney Lather, Deepti Pandita · 2017 · Current treatment options in infectious diseases/Current treatment options in infectious disease
83. Selective Inhibition of Acetyl-Lysine Effector Domains of the Bromodomain Family in Oncology
    Susanne Müller, Hannah Lingard, Stefan Knapp · 2013 · Cancer drug discovery and develogment/Cancer drug discovery and development
84. The Function of Histone Modifications in Chronic Obstructive Pulmonary Disease
    Amin Foroughi Nezhad · 2022 · Preprints.org
85. Crosstalk between NLRP3 Signaling and Histone Deacetylases in Inflammasome-Driven Diseases
    Kathrin Tan, M. Mercedes Rodríguez-Fernández, Tim Keuler, Finn K. Hansen, Michael Gütschow, Günther Weindl, Jose Luis Marco · 2025 · Journal of Medicinal Chemistry
86. Histone deacetylase enzyme activity is not the universal anticancer target of HDAC inhibitors
    Chaitra Rai, Hang Ruan, Xue Li, Wenbo Li, Hyun-Hwan Jeong, Chengchuang Song, Panpan Liu, Yingjie Chang, Hao Fang, Udhaya Kumar. S et al. · 2026 · Signal Transduction and Targeted Therapy
87. Nursing Roles in Cardiac Safety: Romidepsin in Patients With T-Cell Lymphoma
    Jan Hronek, Maureen Reed · 2016 · Oncology nursing forum
88. In silico identification of Histone Deacetylase inhibitors using Streamlined Masked Transformer-based Pretrained features
    Tuan Vinh, Thanh‐Hoang Nguyen‐Vo, Viet-Tuan Le, Xuan-Phuc Phan-Nguyen, Binh Phu Nguyen · 2024 · Methods
89. Research advancements in molecular glues derived from natural product scaffolds: Chemistry, targets, and molecular mechanisms
    Lina Yin, Tingting Niu, Ling Li, Wei Dong Yu, Bo Han, Asma Rehman, Ke‐Wu Zeng · 2025 · Chinese Herbal Medicines
90. The Impact of Post-Translational Regulation of Histone on Cancer Metastasis and Cancer Chemoresistance
    Lin Liu, Ping Yuan, Soner Doğan, Feng Zhu, Qiuhong Duan · 2017 · Current Pharmacology Reports
91. Development of hydroxamate-based histone deacetylase inhibitors of bis-substituted aromatic amides with antitumor activities
    Di Ge, Lina Han, Feifei Yang, Na Zhao, Yang Yang, Hua Zhang, Yihua Chen · 2019 · MedChemComm
92. Navigating into the chemical space between MGCD0103 and SAHA: novel histone deacetylase inhibitors as a promising lead
    Xin Zhang, Peng‐Cheng Lv, Dong‐Dong Li, Wei-Ming Zhang, Hai‐Liang Zhu · 2015 · MedChemComm
93. Das Epigenom
    A. Leipold, Jochen Heß, Karim Zaoui · 2015 · HNO
94. Histone Modifications as Therapeutic Targets for Cancer
    Ling Zhang, Tao Wang, Steven B. Geng, Ke Ren · 2014 · Pharmaceutical and Biosciences Journal
95. Nutrigenomics in the management and prevention of cancer
    Charisse Joy C. Lim, Peter Paul Lim, Renz Romerino M. Pizarro, Hannah Grace B. Segocio, Karanjit Ratta · 2022 · Elsevier eBooks
96. Epigenetic Approaches
    Eva Sahakian, Karrune V. Woan, Alejandro Villagra, Eduardo M. Sotomayor · 2013 · Elsevier eBooks
97. MYC plus class IIa HDAC inhibition drives mitochondrial dysfunction in non-small cell lung cancer
    Jina Park, Ying-Yu Chen, Jennie J. Cao, Julia An, Ray-Whay Chiu Yen, John D. Outen, Stephen B. Baylin, Michael J. Topper · 2025 · Cell Reports
98. Discovery of novel benzyl indole histone deacetylase inhibitors for efficient treatment of colorectal cancer
    Yifan Zhao, Minyue Zhang, Zhenchu Liang, Xing Liu, Weijia Kong, Lang Hu, Yucheng Zhou, Kunlong Lv, Mengfei Zhao, Dongyin Chen et al. · 2025 · Journal of Molecular Structure
99. Scalable and streamlined three-step synthesis of 3-(3-pyridyl)acrylic acid enabled by microreaction technology: Process intensification and integration
    Letao Guo, Mei Yang, Lixia Yang, Mei Han, Wenna Tang, Guangwen Chen · 2026 · Chemical Engineering Science
100. Combinatorial drug repurposing of Valproic acid and Zebularine regulates Krüppel-like factor 4 and β-catenin expression in colon cancer cells
     Jeyalakshmi Kandhavelu, Kumar Subramanian, Natanya Moodley, Kasim Sakran Abass, Chandrabose Sureka, Meenakshisundaram Kandhavelu, Paul Ruff, Clement Penny · 2026 · PLoS ONE